Dr Reddy's Laboratories announced today in Hyderabad the launch of Cresp, a darbepoetin alfa, approved for the treatment of anemia due to chronic kidney disease or chemotherapy. Cresp will be available in vial as well as pre filled syringe form.

Darbepoetin alfa is a modified version of epoetin alfa that is engineered to have a longer half life, increasing the time it remains in blood. this results in a reduced frequency of doses. It provides a simpler and more convenient treatment option for patients as well as physicians as compared to treatment of anemia with epoetin, the current standard of care in India.

Commenting on the launch GV Prasad, vice-chairman and CEO, Dr Reddy's Laboratories said, "Cresp will offer patients in India an improved treatment regimen at affordable pricing. the launch of Cresp by Dr Reddy's is a significant step in redefining the treatment of anemia in India and underscores our commitment to provide affordable and innovative medicines to patients in India."